- Home
- WNW vs SNGX Comparison
WNW vs SNGX Comparison
Compare WNW & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- SNGX
- Stock Information
- Founded
- WNW 2015
- SNGX 1987
- Country
- WNW China
- SNGX United States
- Employees
- WNW N/A
- SNGX N/A
- Industry
- WNW Catalog/Specialty Distribution
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- SNGX Health Care
- Exchange
- WNW Nasdaq
- SNGX Nasdaq
- Market Cap
- WNW 6.9M
- SNGX 6.5M
- IPO Year
- WNW 2020
- SNGX 1987
- Fundamental
- Price
- WNW $1.71
- SNGX $1.93
- Analyst Decision
- WNW
- SNGX
- Analyst Count
- WNW 0
- SNGX 0
- Target Price
- WNW N/A
- SNGX N/A
- AVG Volume (30 Days)
- WNW 26.2K
- SNGX 18.1K
- Earning Date
- WNW 07-07-2025
- SNGX 05-09-2025
- Dividend Yield
- WNW N/A
- SNGX N/A
- EPS Growth
- WNW N/A
- SNGX N/A
- EPS
- WNW 9.06
- SNGX N/A
- Revenue
- WNW $158,485.00
- SNGX $2,342.00
- Revenue This Year
- WNW N/A
- SNGX N/A
- Revenue Next Year
- WNW N/A
- SNGX N/A
- P/E Ratio
- WNW $0.19
- SNGX N/A
- Revenue Growth
- WNW N/A
- SNGX N/A
- 52 Week Low
- WNW $0.95
- SNGX $1.68
- 52 Week High
- WNW $70.00
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- WNW 44.39
- SNGX 49.95
- Support Level
- WNW $1.62
- SNGX $1.86
- Resistance Level
- WNW $1.80
- SNGX $1.97
- Average True Range (ATR)
- WNW 0.12
- SNGX 0.09
- MACD
- WNW 0.02
- SNGX 0.01
- Stochastic Oscillator
- WNW 32.62
- SNGX 70.59
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).